Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

To perform a direct, double-blind, randomised, crossover comparison of subcutaneous and intravenous glucagon-like peptide-1 (GLP-1) in hyperglycaemic subjects with type 2 diabetes naïve to GLP-1-based therapy.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Plasma glucose, total and intact GLP-1, insulin, C-peptide, glucagon and gastrointestinal symptoms were evaluated over 8 h.

The results are presented as mean ± SEM.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Blood Glucose, Hyperglycemia, Hypoglycemic Agents, Insulin and Glycated Hemoglobin.

Author keywords: GLP‐1, clinical physiology, effectiveness, incretin physiology, randomised trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.